Aidoc's CARE1™ becomes the first foundation-model clinical AI cleared by the FDA
In February 2025, the FDA cleared Aidoc's CARE1 — the first foundation-model-powered clinical AI to receive U.S. authorization.
Not a news feed. A curated intelligence platform on the moves that shape clinical AI worldwide.
In February 2025, the FDA cleared Aidoc's CARE1 — the first foundation-model-powered clinical AI to receive U.S. authorization.
April 2025: FDA Breakthrough Device designation for the first AI tool detecting common & rare cancers across tissues.
ISC 2025 evidence across six new clinical studies on the Viz Neuro Suite.
A regulatory unlock for European clinical deployment under MDR.
~$81.25M deal bringing genomics + imaging + pathology under one roof.
ADLT-granted, $4,500-per-test reimbursement — AI-enabled oncology diagnostics matures.
Cardiac imaging + ECG-Low EF software both cleared.
Industry milestone — 295 new authorizations in 2025 alone, 76% radiology.
Longitudinal RWE work that improves real treatment decisions.
Formal authorization for models to evolve post-clearance.
Radiology remains the path of least resistance for new AI medtech.
Multi-spectral imaging predicting wound healing trajectory.
Curated by RauMed Intelligence.